References
- Labrie F. All sex steroids are made intracellularly in peripheral tissues by the mechanism of intracrinology after menopause. J Steroid Biochem Mol Biol 2014 Jun 9. Epub ahead of print
- Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause 2011;18:30–43
- Labrie F. DHEA after menopause – Sole source of sex steroids and potential sex steroid deficiency treatment. Menopause Management 2010;19:14–24
- Labrie F, Labrie C. DHEA and intracrinology at menopause, a positive choice for evolution of the human species. Climacteric 2013;16:205–13
- Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy. II. Neoplasia. Am J Obstet Gynecol 1979;133:537–47
- Baker ME. Co-evolution of steroidogenic and steroid-inactivating enzymes and adrenal and sex steroid receptors. Mol Cell Endocrinol 2004;215:55–62
- Luu-The V, Zhang Y, Poirier D, Labrie F. Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: oxidation-reduction and inhibition. J Steroid Biochem Mol Biol 1995;55:581–7
- Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78:C113–18
- Bélanger B, Bélanger A, Labrie F, et al. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem 1989;32:695–8
- Labrie F, Bélanger A, Bélanger P, et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 2006;99:182–8
- Labrie F, Martel C, Berube R, et al. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. J Steroid Biochem Mol Biol 2013;138:359–67
- Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009;16:907–22
- Labrie F, Archer D, Bouchard C, et al. Effect on intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16:923–31
- Labrie F. Drug Insight: breast cancer prevention and tissue- targeted hormone replacement therapy. Nature Clin Pract Endocrinol Metab 2007;3:584–93
References
- Jamieson DJ, Uyeki TM, Callaghan WM, Meaney-Delman D, Rasmussen SA. What obstetrician-gynecologists should know about ebola: a perspective from the Centers for Disease Control and Prevention. Obstet Gynecol 2014 Sep 8. Epub ahead of print
- Frieden TR, Damon I, Bell BP, Kenyon T, Nichol S. Ebola 2014 – new challenges, new global response and responsibility. N Engl J Med 2014;371:1177–80
- Green A. WHO and partners launch Ebola response plan. Lancet 2014;384:481
References
- Shimbo D, Wang L, Lamonte MJ, et al. The effect of hormone therapy on mean blood pressure and visit-to-visit blood pressure variability in postmenopausal women: results from the Women’s Health Initiative randomized controlled trials. J Hypertens 2014;32:2071–81
- Abramson BL, Melvin RG. Cardiovascular risk in women: focus on hypertension. Can J Cardiol 2014;30:553–9
- Hage FG, Mansur SJ, Xing D, Oparil S. Hypertension in women. Kidney Int Suppl 2013;3:352–6
- Maric-Bilkan C, Gilbert EL, Ryan MJ. Impact of ovarian function on cardiovascular health in women: focus on hypertension. Int J Womens Health 2014;6:131–9
- Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044–9
- The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199–208
- Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: an age-old debate. Hypertension 2008;51:952–9
- White WB. Drospirenone with 17β-estradiol in the postmenopausal woman with hypertension. Climacteric 2007; 10(Suppl 1):25–31
- Chiu CL, Lujic S, Thornton C, O’Loughlin A. Menopausal hormone therapy is associated with having high blood pressure in postmenopausal women: observational cohort study. PLoS One 2012;7:e40260
- Shapiro S, Pines A. Menopausal hormone therapy and risk of hypertension. Climacteric 2012;15:635
- Cannoletta M, Cagnacci A. Modification of blood pressure in postmenopausal women: role of hormone replacement therapy. Int J Womens Health 2014;6:745–57
- Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014;161:249–60
References
- Elam ML, Johnson SA, Hooshmand S, et al. A calcium-collagen chelate dietary supplement attenuates bone loss in postmenopausal women with osteopenia: a randomized controlled trial. J Med Food 2014 Oct 14. Epub ahead of print
- Martin-Bautista E, Martin-Matillas M, Martin-Lagos JA, et al. A nutritional intervention study with hydrolyzed collagen in prepubertal Spanish children: influence on bone modeling biomarkers. J Pediatr Endocrinol Metab 2011;24:147–53
- Cuneo F, Costa-Paiva L, Pinto-Neto AM, Morais SS, Amaya- Farfan J. Effect of dietary supplementation with collagen hydrolysates on bone metabolism of postmenopausal women with low mineral density. Maturitas 2010;65:253–7
- Adam M, Spacek P, Hulejova H, Galianova A, Blahos J. Postmenopausal osteoporosis. Treatment with calcitonin and a diet rich in collagen proteins. Cas Lek Cesk 1996;135:74–8